Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Rybelsus (semaglutide) and Ozempic (semaglutide) are both medications used to treat Type 2 diabetes and belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class. They share the same active ingredient, semaglutide, and can help lower blood sugar levels. However, they differ in their form and dosing. Rybelsus is an oral tablet taken once daily, while Ozempic is a subcutaneous (under the skin) injection given once a week. Both Rybelsus and Ozempic are only available as brand-name medications. Both can cause side effects like nausea, vomiting, and diarrhea. Additionally, Ozempic is FDA-approved to lower the risk of heart attack, stroke, and death in adults with Type 2 diabetes and heart disease, an indication not shared by Rybelsus. Both medications carry a risk of thyroid cancer and should not be used if you have a personal or family history of certain thyroid cancers.
Rybelsus (semaglutide)
Ozempic (semaglutide)
Rybelsus (semaglutide)
Ozempic (semaglutide)
Summary of Rybelsus vs. Ozempic
Summary for GLP-1 agonist
Prescription only
Rybelsus (semaglutide) is a brand-name GLP-1 agonist that helps lower blood sugar in adults with Type 2 diabetes. It's also FDA approved to help reduce the risk of heart attack, stroke, and heart-related death in people with Type 2 diabetes who are at risk for these events. The medication comes as a pill that's taken by mouth once a day, at least 30 minutes before you eat, drink, or take any other medications by mouth. It’s used along with diet and exercise, and might also help with weight loss. Common side effects include nausea, stomach pain, and diarrhea.
Summary for GLP-1 agonist
Prescription only
Ozempic (semaglutide) is a prescription injection used with diet and exercise to help manage Type 2 diabetes in adults. It's also FDA approved to lower the risk of heart attack, stroke, and heart-related death in those with Type 2 diabetes and heart disease. In addition, it can reduce the risk of worsening kidney problems in people with Type 2 diabetes and chronic kidney disease (CKD). Ozempic (semaglutide) is a GLP-1 agonist that's injected under the skin once a week. Common side effects include nausea, vomiting, and diarrhea.